logo

Endocrine Society of Australia Position Statement on Testosterone

The Endocrine Society of Australia (ESA) Position Statement on Male Hypogonadism (part 1): Assessment and Indications for Testosterone Therapy has just been published in the Medical Journal of Australia, updating the ESA guidelines from 2000.

testosterone-vial-343x480Developed by leading Australian endocrinologists, including Andrology Australia Director Professor Rob McLachlan, the position statement supports the use of testosterone replacement therapy in men of any age with confirmed androgen deficiency. Androgen deficiency conditions where testosterone therapy will be of benefit include Klinefelter’s syndrome, pituitary tumours and surgery or radiation that has damaged the testes. The purpose of testosterone replacement therapy in these conditions is to restore testosterone levels to normal.

There is currently not sufficient evidence to support testosterone treatment for other conditions where there may be lowered testosterone levels without a clear androgen deficiency diagnosis, such as in older men with chronic diseases. Further research is needed to see if testosterone therapy in these cases is safe and effective.

Men should speak to their treating doctor before making any decisions about treatment with testosterone. The ESA statement will help doctors in identifying and diagnosing patients with androgen deficiency who would benefit from testosterone treatment.

To help guide medical professionals, Andrology Australia, in cooperation with the ESA developed an advisory note outlining the Pharmaceutical Benefits Schedule (PBS) criteria for prescribing testosterone (for medical professionals).

In summary:

The Endocrine Society of Australia (ESA) Position Statement on Male Hypogonadism (part 1): Assessment and Indications for Testosterone Therapy has just been published in the Medical Journal of Australia, updating the ESA guidelines from 2000. Developed by leading Australian endocrinologists, … Continue reading

Men's health in Primary Health Care

The text and summary of this article may be used by primary health care organisations (such as Medicare Locals and Community Health Services) and peak health professional organisations (such as APNA and AAPM) to inform their staff and/or health professional members.

Organisations such as those listed above may republish this article in their own publications (including newsletters, web sites, fax and email bulletins) for their own staff and to health professional members.

Note that copyright applies to this material and the following credit must be included when republishing:
Copyright © Andrology Australia (www.andrologyaustralia.org)

Unless specified otherwise, non-text elements (e.g. images, video) may not be republished.

Read more articles on the 'Primary health care' blog.

This entry was posted in Clinical management, Men's health, Primary health care, Testosterone and tagged , . Bookmark the permalink.
Website by Essendon Creative